Abstract: Hypertrophic cardiomyopathy( HCM) is defined by the presence of increased left ventricular( LV) wall thickness that is not solely explained by abnormal loading conditions. Although HCM is one type of common cardiovascular diseases,it lacks large-scale randomized controlled clinical studies.Almost 70% of HCM patients present with left ventricular outflow tract obstruction( LVOTO),an important clinical decisive factor for symptoms such as dyspnea,chest pain,palpitation,and syncope. LVOTO is one of the therapy targets for either drug therapy or invasive therapy including ventricular septum resection or ventricular septal intervention such as anhydrous alcohol septum ablation( ASA). This article will review the research advances in ventricular septal intervention in HCM.